Supernus Pharmaceuticals (Nasdaq: SUPN) marked the five-year anniversary of the FDA approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE